108 related articles for article (PubMed ID: 24350997)
1. An incidence model of the cost of advanced prostate cancer in Spain.
Hart WM; Nazir J; Baskin-Bey E
J Med Econ; 2014 Feb; 17(2):125-31. PubMed ID: 24350997
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.
Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; ; Cantalapiedra A; Pedrosa E
BJU Int; 2012 Dec; 110(11 Pt B):E701-6. PubMed ID: 22989066
[TBL] [Abstract][Full Text] [Related]
3. Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data.
Stokes ME; Black L; Benedict A; Roehrborn CG; Albertsen P
Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):278-84. PubMed ID: 20212521
[TBL] [Abstract][Full Text] [Related]
4. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK.
Fourcade RO; Benedict A; Black LK; Stokes ME; Alcaraz A; Castro R
BJU Int; 2010 Jan; 105(1):49-56. PubMed ID: 20132102
[TBL] [Abstract][Full Text] [Related]
5. Advanced prostate cancer risk in relation to toenail selenium levels.
Geybels MS; Verhage BA; van Schooten FJ; Goldbohm RA; van den Brandt PA
J Natl Cancer Inst; 2013 Sep; 105(18):1394-401. PubMed ID: 23878355
[TBL] [Abstract][Full Text] [Related]
6. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population.
Alemayehu B; Buysman E; Parry D; Becker L; Nathan F
J Med Econ; 2010; 13(2):351-61. PubMed ID: 20491610
[TBL] [Abstract][Full Text] [Related]
7. [National prostate cancer registry 2010 in Spain].
Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; Cantalapiedra A; Pedrosa E
Actas Urol Esp; 2013 Jan; 37(1):12-9. PubMed ID: 23102541
[TBL] [Abstract][Full Text] [Related]
8. First-year costs of treating prostate cancer: estimates from SEER-Medicare data.
Roehrborn CG; Albertsen P; Stokes ME; Black L; Benedict A
Prostate Cancer Prostatic Dis; 2009; 12(4):355-60. PubMed ID: 19468284
[TBL] [Abstract][Full Text] [Related]
9. A simulation model of the cost of the incidence of IDDM in Spain.
Hart WM; Espinosa C; Rovira J
Diabetologia; 1997 Mar; 40(3):311-8. PubMed ID: 9084970
[TBL] [Abstract][Full Text] [Related]
10. Healthcare costs associated with prostate cancer: estimates from a population-based study.
Krahn MD; Zagorski B; Laporte A; Alibhai SM; Bremner KE; Tomlinson G; Warde P; Naglie G
BJU Int; 2010 Feb; 105(3):338-46. PubMed ID: 19594734
[TBL] [Abstract][Full Text] [Related]
11. Lifetime economic burden of prostate cancer.
Stokes ME; Ishak J; Proskorovsky I; Black LK; Huang Y
BMC Health Serv Res; 2011 Dec; 11():349. PubMed ID: 22204308
[TBL] [Abstract][Full Text] [Related]
12. The cost of prostate cancer chemoprevention: a decision analysis model.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
[TBL] [Abstract][Full Text] [Related]
13. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
CMAJ; 2000 Apr; 162(7):977-83. PubMed ID: 10763395
[TBL] [Abstract][Full Text] [Related]
14. Cumulative cost pattern comparison of prostate cancer treatments.
Wilson LS; Tesoro R; Elkin EP; Sadetsky N; Broering JM; Latini DM; DuChane J; Mody RR; Carroll PR
Cancer; 2007 Feb; 109(3):518-27. PubMed ID: 17186528
[TBL] [Abstract][Full Text] [Related]
15. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
CMAJ; 2000 Apr; 162(7):987-92. PubMed ID: 10763396
[TBL] [Abstract][Full Text] [Related]
16. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
[TBL] [Abstract][Full Text] [Related]
17. Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
[TBL] [Abstract][Full Text] [Related]
18. [Epidemiological trends in prostate cancer over the last years].
Luján Galán M; Páez Borda A; Chiva Robles V; Santonja Garriga C; Romero Cajigal I; Berenguer Sánchez A
Arch Esp Urol; 2004 Oct; 57(8):817-25. PubMed ID: 15560270
[TBL] [Abstract][Full Text] [Related]
19. Economical data and advanced prostate carcinoma: do we need new guidelines for decision making?
Rohde V; Wellmann A; Fogt F; Weidner W; Katalinic A
Oncol Rep; 2002; 9(6):1185-8. PubMed ID: 12375016
[TBL] [Abstract][Full Text] [Related]
20. Health related quality of life and direct medical care cost in newly diagnosed younger men with prostate cancer.
Jayadevappa R; Bloom BS; Chhatre S; Fomberstein KM; Wein AJ; Malkowicz SB
J Urol; 2005 Sep; 174(3):1059-64; discussion 1064. PubMed ID: 16094058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
